Pharma & Healthcare

Global Long-acting ESAs Market Outlook, In‑Depth Analysis & Forecast to 2031

Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Long-acting ESAs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Kyowa Kirin
Amgen
Dr. Reddy's Laboratories
Roche
Hansoh Pharma
Cipla
Sanwa Kagaku Kenkyusho
Kissei Pharmaceutical
Kyowa Hakko Kirin
Torrent Pharmaceuticals
CKD Pharma
Segment by Type
Darbepoetin Alfa
Methoxy Polyethylene Glycol-Epoetin Beta
Pegmolesatide
Segment by Application
Renal Anemia
Cancer
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Long-acting ESAs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Long-acting ESAs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Long-acting ESAs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Darbepoetin Alfa
1.2.3 Methoxy Polyethylene Glycol-Epoetin Beta
1.2.4 Pegmolesatide
1.3 Market Segmentation by Application
1.3.1 Global Long-acting ESAs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Renal Anemia
1.3.3 Cancer
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long-acting ESAs Revenue Estimates and Forecasts 2020-2031
2.2 Global Long-acting ESAs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Long-acting ESAs Sales Estimates and Forecasts 2020-2031
2.4 Global Long-acting ESAs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Long-acting ESAs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Long-acting ESAs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Darbepoetin Alfa Market Size by Manufacturers
3.5.2 Methoxy Polyethylene Glycol-Epoetin Beta Market Size by Manufacturers
3.5.3 Pegmolesatide Market Size by Manufacturers
3.6 Global Long-acting ESAs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Long-acting ESAs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Long-acting ESAs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Long-acting ESAs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Long-acting ESAs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Long-acting ESAs Sales and Revenue by Type (2020-2031)
6.4 North America Long-acting ESAs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Long-acting ESAs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Long-acting ESAs Sales and Revenue by Type (2020-2031)
7.4 Europe Long-acting ESAs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Long-acting ESAs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Long-acting ESAs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Long-acting ESAs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Long-acting ESAs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Long-acting ESAs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Long-acting ESAs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Long-acting ESAs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Long-acting ESAs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Long-acting ESAs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Long-acting ESAs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Kyowa Kirin
11.1.1 Kyowa Kirin Corporation Information
11.1.2 Kyowa Kirin Business Overview
11.1.3 Kyowa Kirin Long-acting ESAs Product Models, Descriptions and Specifications
11.1.4 Kyowa Kirin Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Kyowa Kirin Long-acting ESAs Sales by Product in 2024
11.1.6 Kyowa Kirin Long-acting ESAs Sales by Application in 2024
11.1.7 Kyowa Kirin Long-acting ESAs Sales by Geographic Area in 2024
11.1.8 Kyowa Kirin Long-acting ESAs SWOT Analysis
11.1.9 Kyowa Kirin Recent Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Business Overview
11.2.3 Amgen Long-acting ESAs Product Models, Descriptions and Specifications
11.2.4 Amgen Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Amgen Long-acting ESAs Sales by Product in 2024
11.2.6 Amgen Long-acting ESAs Sales by Application in 2024
11.2.7 Amgen Long-acting ESAs Sales by Geographic Area in 2024
11.2.8 Amgen Long-acting ESAs SWOT Analysis
11.2.9 Amgen Recent Developments
11.3 Dr. Reddy's Laboratories
11.3.1 Dr. Reddy's Laboratories Corporation Information
11.3.2 Dr. Reddy's Laboratories Business Overview
11.3.3 Dr. Reddy's Laboratories Long-acting ESAs Product Models, Descriptions and Specifications
11.3.4 Dr. Reddy's Laboratories Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Dr. Reddy's Laboratories Long-acting ESAs Sales by Product in 2024
11.3.6 Dr. Reddy's Laboratories Long-acting ESAs Sales by Application in 2024
11.3.7 Dr. Reddy's Laboratories Long-acting ESAs Sales by Geographic Area in 2024
11.3.8 Dr. Reddy's Laboratories Long-acting ESAs SWOT Analysis
11.3.9 Dr. Reddy's Laboratories Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Business Overview
11.4.3 Roche Long-acting ESAs Product Models, Descriptions and Specifications
11.4.4 Roche Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Roche Long-acting ESAs Sales by Product in 2024
11.4.6 Roche Long-acting ESAs Sales by Application in 2024
11.4.7 Roche Long-acting ESAs Sales by Geographic Area in 2024
11.4.8 Roche Long-acting ESAs SWOT Analysis
11.4.9 Roche Recent Developments
11.5 Hansoh Pharma
11.5.1 Hansoh Pharma Corporation Information
11.5.2 Hansoh Pharma Business Overview
11.5.3 Hansoh Pharma Long-acting ESAs Product Models, Descriptions and Specifications
11.5.4 Hansoh Pharma Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Hansoh Pharma Long-acting ESAs Sales by Product in 2024
11.5.6 Hansoh Pharma Long-acting ESAs Sales by Application in 2024
11.5.7 Hansoh Pharma Long-acting ESAs Sales by Geographic Area in 2024
11.5.8 Hansoh Pharma Long-acting ESAs SWOT Analysis
11.5.9 Hansoh Pharma Recent Developments
11.6 Cipla
11.6.1 Cipla Corporation Information
11.6.2 Cipla Business Overview
11.6.3 Cipla Long-acting ESAs Product Models, Descriptions and Specifications
11.6.4 Cipla Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Cipla Recent Developments
11.7 Sanwa Kagaku Kenkyusho
11.7.1 Sanwa Kagaku Kenkyusho Corporation Information
11.7.2 Sanwa Kagaku Kenkyusho Business Overview
11.7.3 Sanwa Kagaku Kenkyusho Long-acting ESAs Product Models, Descriptions and Specifications
11.7.4 Sanwa Kagaku Kenkyusho Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Sanwa Kagaku Kenkyusho Recent Developments
11.8 Kissei Pharmaceutical
11.8.1 Kissei Pharmaceutical Corporation Information
11.8.2 Kissei Pharmaceutical Business Overview
11.8.3 Kissei Pharmaceutical Long-acting ESAs Product Models, Descriptions and Specifications
11.8.4 Kissei Pharmaceutical Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Kissei Pharmaceutical Recent Developments
11.9 Kyowa Hakko Kirin
11.9.1 Kyowa Hakko Kirin Corporation Information
11.9.2 Kyowa Hakko Kirin Business Overview
11.9.3 Kyowa Hakko Kirin Long-acting ESAs Product Models, Descriptions and Specifications
11.9.4 Kyowa Hakko Kirin Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Kyowa Hakko Kirin Recent Developments
11.10 Torrent Pharmaceuticals
11.10.1 Torrent Pharmaceuticals Corporation Information
11.10.2 Torrent Pharmaceuticals Business Overview
11.10.3 Torrent Pharmaceuticals Long-acting ESAs Product Models, Descriptions and Specifications
11.10.4 Torrent Pharmaceuticals Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Torrent Pharmaceuticals Recent Developments
11.11 CKD Pharma
11.11.1 CKD Pharma Corporation Information
11.11.2 CKD Pharma Business Overview
11.11.3 CKD Pharma Long-acting ESAs Product Models, Descriptions and Specifications
11.11.4 CKD Pharma Long-acting ESAs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 CKD Pharma Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Long-acting ESAs Industry Chain
12.2 Long-acting ESAs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Long-acting ESAs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Long-acting ESAs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Long-acting ESAs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Long-acting ESAs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Long-acting ESAs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Long-acting ESAs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Long-acting ESAs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Long-acting ESAs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Long-acting ESAs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Long-acting ESAs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Long-acting ESAs Sales by Region (2020-2025) & (K Units)
Table 8. Global Long-acting ESAs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Long-acting ESAs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Long-acting ESAs Sales Share by Manufacturers (2020-2025)
Table 12. Global Long-acting ESAs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Long-acting ESAs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Long-acting ESAs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting ESAs as of 2024)
Table 16. Global Long-acting ESAs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Long-acting ESAs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Long-acting ESAs Manufacturing Base and Headquarters
Table 19. Global Long-acting ESAs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Long-acting ESAs Sales by Type (2020-2025) & (K Units)
Table 23. Global Long-acting ESAs Sales by Type (2026-2031) & (K Units)
Table 24. Global Long-acting ESAs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Long-acting ESAs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Long-acting ESAs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Long-acting ESAs Sales by Application (2020-2025) & (K Units)
Table 29. Global Long-acting ESAs Sales by Application (2026-2031) & (K Units)
Table 30. Long-acting ESAs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Long-acting ESAs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Long-acting ESAs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Long-acting ESAs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Long-acting ESAs Growth Accelerators and Market Barriers
Table 37. North America Long-acting ESAs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Long-acting ESAs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Long-acting ESAs Growth Accelerators and Market Barriers
Table 40. Europe Long-acting ESAs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Long-acting ESAs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Long-acting ESAs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Long-acting ESAs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Long-acting ESAs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Long-acting ESAs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Long-acting ESAs Investment Opportunities and Key Challenges
Table 47. Central and South America Long-acting ESAs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Long-acting ESAs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Long-acting ESAs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Kyowa Kirin Corporation Information
Table 51. Kyowa Kirin Description and Major Businesses
Table 52. Kyowa Kirin Product Models, Descriptions and Specifications
Table 53. Kyowa Kirin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Kyowa Kirin Sales Value Proportion by Product in 2024
Table 55. Kyowa Kirin Sales Value Proportion by Application in 2024
Table 56. Kyowa Kirin Sales Value Proportion by Geographic Area in 2024
Table 57. Kyowa Kirin Long-acting ESAs SWOT Analysis
Table 58. Kyowa Kirin Recent Developments
Table 59. Amgen Corporation Information
Table 60. Amgen Description and Major Businesses
Table 61. Amgen Product Models, Descriptions and Specifications
Table 62. Amgen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Amgen Sales Value Proportion by Product in 2024
Table 64. Amgen Sales Value Proportion by Application in 2024
Table 65. Amgen Sales Value Proportion by Geographic Area in 2024
Table 66. Amgen Long-acting ESAs SWOT Analysis
Table 67. Amgen Recent Developments
Table 68. Dr. Reddy's Laboratories Corporation Information
Table 69. Dr. Reddy's Laboratories Description and Major Businesses
Table 70. Dr. Reddy's Laboratories Product Models, Descriptions and Specifications
Table 71. Dr. Reddy's Laboratories Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Dr. Reddy's Laboratories Sales Value Proportion by Product in 2024
Table 73. Dr. Reddy's Laboratories Sales Value Proportion by Application in 2024
Table 74. Dr. Reddy's Laboratories Sales Value Proportion by Geographic Area in 2024
Table 75. Dr. Reddy's Laboratories Long-acting ESAs SWOT Analysis
Table 76. Dr. Reddy's Laboratories Recent Developments
Table 77. Roche Corporation Information
Table 78. Roche Description and Major Businesses
Table 79. Roche Product Models, Descriptions and Specifications
Table 80. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Roche Sales Value Proportion by Product in 2024
Table 82. Roche Sales Value Proportion by Application in 2024
Table 83. Roche Sales Value Proportion by Geographic Area in 2024
Table 84. Roche Long-acting ESAs SWOT Analysis
Table 85. Roche Recent Developments
Table 86. Hansoh Pharma Corporation Information
Table 87. Hansoh Pharma Description and Major Businesses
Table 88. Hansoh Pharma Product Models, Descriptions and Specifications
Table 89. Hansoh Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Hansoh Pharma Sales Value Proportion by Product in 2024
Table 91. Hansoh Pharma Sales Value Proportion by Application in 2024
Table 92. Hansoh Pharma Sales Value Proportion by Geographic Area in 2024
Table 93. Hansoh Pharma Long-acting ESAs SWOT Analysis
Table 94. Hansoh Pharma Recent Developments
Table 95. Cipla Corporation Information
Table 96. Cipla Description and Major Businesses
Table 97. Cipla Product Models, Descriptions and Specifications
Table 98. Cipla Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Cipla Recent Developments
Table 100. Sanwa Kagaku Kenkyusho Corporation Information
Table 101. Sanwa Kagaku Kenkyusho Description and Major Businesses
Table 102. Sanwa Kagaku Kenkyusho Product Models, Descriptions and Specifications
Table 103. Sanwa Kagaku Kenkyusho Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Sanwa Kagaku Kenkyusho Recent Developments
Table 105. Kissei Pharmaceutical Corporation Information
Table 106. Kissei Pharmaceutical Description and Major Businesses
Table 107. Kissei Pharmaceutical Product Models, Descriptions and Specifications
Table 108. Kissei Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Kissei Pharmaceutical Recent Developments
Table 110. Kyowa Hakko Kirin Corporation Information
Table 111. Kyowa Hakko Kirin Description and Major Businesses
Table 112. Kyowa Hakko Kirin Product Models, Descriptions and Specifications
Table 113. Kyowa Hakko Kirin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Kyowa Hakko Kirin Recent Developments
Table 115. Torrent Pharmaceuticals Corporation Information
Table 116. Torrent Pharmaceuticals Description and Major Businesses
Table 117. Torrent Pharmaceuticals Product Models, Descriptions and Specifications
Table 118. Torrent Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Torrent Pharmaceuticals Recent Developments
Table 120. CKD Pharma Corporation Information
Table 121. CKD Pharma Description and Major Businesses
Table 122. CKD Pharma Product Models, Descriptions and Specifications
Table 123. CKD Pharma Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. CKD Pharma Recent Developments
Table 125. Key Raw Materials Distribution
Table 126. Raw Materials Key Suppliers
Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 128. Milestones in Production Technology Evolution
Table 129. Distributors List
Table 130. Market Trends and Market Evolution
Table 131. Market Drivers and Opportunities
Table 132. Market Challenges, Risks, and Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources


List of Figures
Figure 1. Long-acting ESAs Product Picture
Figure 2. Global Long-acting ESAs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Darbepoetin Alfa Product Picture
Figure 4. Methoxy Polyethylene Glycol-Epoetin Beta Product Picture
Figure 5. Pegmolesatide Product Picture
Figure 6. Global Long-acting ESAs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Renal Anemia
Figure 8. Cancer
Figure 9. Other
Figure 10. Long-acting ESAs Report Years Considered
Figure 11. Global Long-acting ESAs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 13. Global Long-acting ESAs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Long-acting ESAs Revenue Market Share by Region (2020-2031)
Figure 15. Global Long-acting ESAs Sales (2020-2031) & (K Units)
Figure 16. Global Long-acting ESAs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Long-acting ESAs Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Long-acting ESAs Sales Volume Market Share in 2024
Figure 19. Global Long-acting ESAs Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Darbepoetin Alfa Revenue Market Share by Manufacturer in 2024
Figure 22. Methoxy Polyethylene Glycol-Epoetin Beta Revenue Market Share by Manufacturer in 2024
Figure 23. Pegmolesatide Revenue Market Share by Manufacturer in 2024
Figure 24. Global Long-acting ESAs Sales Market Share by Type (2020-2031)
Figure 25. Global Long-acting ESAs Revenue Market Share by Type (2020-2031)
Figure 26. Global Long-acting ESAs Sales Market Share by Application (2020-2031)
Figure 27. Global Long-acting ESAs Revenue Market Share by Application (2020-2031)
Figure 28. North America Long-acting ESAs Sales YoY (2020-2031) & (K Units)
Figure 29. North America Long-acting ESAs Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Long-acting ESAs Sales Revenue (US$ Million) in 2024
Figure 31. North America Long-acting ESAs Sales Volume (K Units) by Type (2020- 2031)
Figure 32. North America Long-acting ESAs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Long-acting ESAs Sales Volume (K Units) by Application (2020-2031)
Figure 34. North America Long-acting ESAs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Long-acting ESAs Sales YoY (2020-2031) & (K Units)
Figure 39. Europe Long-acting ESAs Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Long-acting ESAs Sales Revenue (US$ Million) in 2024
Figure 41. Europe Long-acting ESAs Sales Volume (K Units) by Type (2020-2031)
Figure 42. Europe Long-acting ESAs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Long-acting ESAs Sales Volume (K Units) by Application (2020-2031)
Figure 44. Europe Long-acting ESAs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 46. France Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Long-acting ESAs Sales YoY (2020-2031) & (K Units)
Figure 51. Asia-Pacific Long-acting ESAs Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Long-acting ESAs Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Long-acting ESAs Sales Volume (K Units) by Type (2020- 2031)
Figure 54. Asia-Pacific Long-acting ESAs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Long-acting ESAs Sales Volume (K Units) by Application (2020-2031)
Figure 56. Asia-Pacific Long-acting ESAs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 61. India Long-acting ESAs Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Long-acting ESAs Sales YoY (2020-2031) & (K Units)
Figure 63. Central and South America Long-acting ESAs Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Long-acting ESAs Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Long-acting ESAs Sales Volume (K Units) by Type (2021-2031)
Figure 66. Central and South America Long-acting ESAs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Long-acting ESAs Sales Volume (K Units) by Application (2020-2031)
Figure 68. Central and South America Long-acting ESAs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Long-acting ESAs Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Long-acting ESAs Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Long-acting ESAs Sales YoY (2020-2031) & (K Units)
Figure 72. Middle East and Africa Long-acting ESAs Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Long-acting ESAs Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Long-acting ESAs Sales Volume (K Units) by Type (2021-2031)
Figure 75. South America Long-acting ESAs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Long-acting ESAs Sales Volume (K Units) by Application (2020-2031)
Figure 77. Middle East and Africa Long-acting ESAs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Long-acting ESAs Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Long-acting ESAs Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Long-acting ESAs Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Long-acting ESAs Revenue (2020-2025) & (US$ Million)
Figure 82. Long-acting ESAs Industry Chain Mapping
Figure 83. Regional Long-acting ESAs Manufacturing Base Distribution (%)
Figure 84. Global Long-acting ESAs Production Market Share by Region (2020-2031)
Figure 85. Long-acting ESAs Production Process
Figure 86. Regional Long-acting ESAs Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies